Australia's most trusted
source of pharma news
Posted 27 February 2026 AM
MSD has led a call for action to improve diagnosis and treatment of Pulmonary Arterial Hypertension across the Asia Pacific.
The Declaration for Action on Pulmonary Arterial Hypertension (PAH): Advancing Early Diagnosis, Equitable Access, and Societal Momentum was written with patient groups, healthcare providers, and non-government organisations across the region to pledge a shared commitment to strengthen PAH awareness, speed diagnosis, and improve care in the Asia Pacific, which accounts for around 60 per cent of all PAH deaths worldwide.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.